Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Beam Therapeutics Inc (BEAM)
Beam Therapeutics Inc (BEAM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,151,705
  • Shares Outstanding, K 81,504
  • Annual Sales, $ 60,920 K
  • Annual Income, $ -289,090 K
  • 60-Month Beta 1.69
  • Price/Sales 38.46
  • Price/Cash Flow N/A
  • Price/Book 2.92
Trade BEAM with:

Options Overview Details

View History
  • Implied Volatility 64.06% ( -6.65%)
  • Historical Volatility 95.29%
  • IV Percentile 18%
  • IV Rank 32.55%
  • IV High 94.87% on 02/13/23
  • IV Low 49.18% on 09/19/23
  • Put/Call Vol Ratio 0.29
  • Today's Volume 1,159
  • Volume Avg (30-Day) 713
  • Put/Call OI Ratio 0.21
  • Today's Open Interest 13,617
  • Open Int (30-Day) 13,547

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -1.16
  • Number of Estimates 5
  • High Estimate -0.66
  • Low Estimate -1.46
  • Prior Year -0.54
  • Growth Rate Est. (year over year) -114.81%

Price Performance

See More
Period Period Low Period High Performance
1-Month
18.85 +40.05%
on 11/13/23
31.09 -15.09%
on 11/20/23
+3.50 (+15.28%)
since 11/08/23
3-Month
16.95 +55.75%
on 10/23/23
31.09 -15.09%
on 11/20/23
+0.85 (+3.33%)
since 09/08/23
52-Week
16.95 +55.75%
on 10/23/23
51.60 -48.84%
on 12/13/22
-18.29 (-40.93%)
since 12/08/22

Most Recent Stories

More News
You Don't Have to Pick a Winner in Gene-Editing. Do This Instead.

The gene-editing revolution is unfolding at a record pace. Still, risks abound, and picking individual stocks may not be the wisest approach.

CRSP : 64.54 (-8.08%)
BEAM : 26.40 (-8.17%)
CRBU : 5.81 (-2.35%)
EDIT : 10.51 (-3.58%)
NTLA : 29.02 (-2.55%)
PRME : 8.50 (-0.70%)
VERV : 12.79 (-0.93%)
LLY : 598.05 (+1.66%)
REGN : 840.14 (-1.06%)
VRTX : 350.15 (-1.07%)
ARKG : 28.60 (-0.38%)
HOOD : 11.73 (+2.18%)
Is Beam Therapeutics Stock a Buy Now?

It has plenty of money, but it'll be facing plenty of competition, too.

PFE : 28.78 (+0.52%)
BEAM : 26.40 (-8.17%)
3 Monster Stocks in the Making

These stocks could grow much larger over the next few years.

BEAM : 26.40 (-8.17%)
CRSP : 64.54 (-8.08%)
SRPT : 87.03 (-1.56%)
2 Magnificent Growth Stocks That Might Be Badly Mispriced Right Now

These two beaten-down growth stocks could be brilliant buys for risk-tolerant investors.

CRSP : 64.54 (-8.08%)
BEAM : 26.40 (-8.17%)
Why Beam and Verve Therapeutics Shares Soared While Eli Lilly Soured Today

Lilly is putting its money where its mouth is with its purchase of cutting-edge medical technology.

BEAM : 26.40 (-8.17%)
VERV : 12.79 (-0.93%)
LLY : 598.05 (+1.66%)
After Cutting 20% of Its Staff, Is Beam Therapeutics Still a Buy?

Some of the strategic shifts proposed by management are for the better.

BEAM : 26.40 (-8.17%)
5 Reasons Beam Therapeutics Remains a Risky Stock

Shares of the gene-editing biotech might not have hit rock bottom yet.

BEAM : 26.40 (-8.17%)
Cathie Wood Loves This Beaten-Down Stock. But Is It in Trouble?

Beam Therapeutics' pipeline will look slimmer going forward.

BEAM : 26.40 (-8.17%)
Beam Therapeutics Stock: Bear vs. Bull

This biotech has a few factors in its corner, but it also faces a difficult path.

PFE : 28.78 (+0.52%)
BEAM : 26.40 (-8.17%)
1 Risky Biotech Stock to Consider Buying, and 1 to Avoid

Both are in a race against time to commercialize a medicine before cash runs out.

BEAM : 26.40 (-8.17%)
EDIT : 10.51 (-3.58%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Beam Therapeutics Inc. is a biotechnology company. It engages in developing precision genetic medicines through base editing. Beam Therapeutics Inc. is based in Cambridge, Massachusetts.

See More

Key Turning Points

3rd Resistance Point 30.53
2nd Resistance Point 29.66
1st Resistance Point 28.03
Last Price 26.40
1st Support Level 25.53
2nd Support Level 24.66
3rd Support Level 23.03

See More

52-Week High 51.60
Fibonacci 61.8% 38.36
Fibonacci 50% 34.28
Fibonacci 38.2% 30.19
Last Price 26.40
52-Week Low 16.95

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar